Nanotechnology Now - Press Release: Research and Markets: Updated Cardiovascular Drug Delivery Study - Examining Technological Innovation, Key Players and Markets (2010 to 2020)

Home > Press > Research and Markets: Updated Cardiovascular Drug Delivery Study - Examining Technological Innovation, Key Players and Markets (2010 to 2020)

Abstract:
Research and Markets has announced the addition of Jain PharmaBiotech's updated report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their extensive offering of medical industry research publications.

Research and Markets: Updated Cardiovascular Drug Delivery Study - Examining Technological Innovation, Key Players and Markets (2010 to 2020)

Dublin, Ireland | Posted on October 4th, 2011

Advances in molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to treatment. Gene therapy is not only a sophisticated method of drug delivery, it may in time need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system.

Cardiovascular Drug Delivery - Technologies, Markets and Companies begins by introducing molecular cardiology and examines its relationship to biotechnology and drug delivery systems. Analysis of drug delivery is provided at three levels:

routes of drug delivery
formulations
applications to various diseases

Complete sections in Cardiovascular Drug Delivery - Technologies, Markets and Companies are devoted to cell and gene therapies, including antisense and RNA interference, as they are currently at the cutting edge of therapeutics delivery methodology. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

One of the most exciting areas of biomedical engineering is cell-selective drug delivery, which involves the optimising the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. Jain PharmaBiotech applies these concepts to targeted drug delivery to the cardiovascular system, while devices for drug delivery to the cardiovascular system are also examined.

The role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed, as is cardioprotection. A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.

The treatment of heart disease is being improved with the development of emerging cell-based therapeutic strategies. Cell grafting or mobilizing endogenous cells are potentially, particularly fruitful for heart repair - where the slight capacity for cardiomyocyte proliferation probably contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium.

The cardiovascular drug delivery markets are estimated for the years 2010 to 2020 on the basis of epidemiology and total markets for cardiovascular therapeutics. Markets for drug-eluting stents are calculated separately.

Key Topics Covered:

Cardiovascular Diseases
Methods for Drug Delivery to the Cardiovascular System
Cell Therapy for Cardiovascular Disorders
Gene Therapy for Cardiovascular Disorders
Drug-Eluting Stents
Markets for Cardiovascular Drug Delivery
Companies involved in Cardiovascular Drug Delivery
Profiles of companies
Collaborations
References